SCHEMBL4606495

SCHEMBL4606495

COC(OCC(CO)OCc1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RCE1 Q9Y256 1/20 0.40
KMT2A Q03164 2/20 0.39
HTT P42858 4/20 0.38
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
TACR1 P25103 2/20 0.36
MAPT P10636 2/20 0.35
SLC1A3 P43003 2/20 0.35
SLC1A2 P43004 2/20 0.35
SLC1A1 P43005 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RECQL P46063 1/20 0.35
NPC1 O15118 1/20 0.35
AOC3 Q16853 1/20 0.35
HTR1A P08908 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3072490 0.82 SLC1A3 (0.41) RCE1KMT2AHTTMAPTSLC1A3
SCHEMBL10566320 0.82 SLC1A3 (0.41) RCE1KMT2AHTTMAPTSLC1A3
SCHEMBL19993652 0.82 SLC1A3 (0.41) RCE1KMT2AHTTMAPTSLC1A3
SCHEMBL4413012 0.82 SLC6A2 (0.45) RCE1KMT2AHTTSLC6A2SLC6A4
SCHEMBL19546244 0.78 SCN1A (0.36) HTTSLC6A2SLC6A4SLC6A3MAPT
SCHEMBL227684 0.77 TSHR (0.48) KMT2ASLC6A2SLC6A4SLC6A3SLC1A3
SCHEMBL6578270 0.76 CYP1A2 (0.51) KMT2AHTTMAPTMEN1CYP1A2
SCHEMBL19043237 0.76 TSHR (0.45) KMT2ATACR1MAPTSLC1A3SLC1A2
SCHEMBL4537628 0.76 CA1 (0.51) KMT2AHTTTACR1SLC1A3SLC1A2
SCHEMBL8904530 0.76 CA1 (0.51) KMT2AHTTTACR1SLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942861-A2 MULTI-PHASE PERSONAL CARE COMPOSITION COMPRISING A STABILIZING PERFUME COMPOSITION The Procter and Gamble Company (US) 2008-07-16 EP disclosed
US-20070135319-A1 Multi-phase personal care composition comprising a stabilizing perfume composition PROCTER & GAMBLE COMPANY, THE 2007-06-14 US disclosed
WO-2007052224-A2 MULTI-PHASE PERSONAL CARE COMPOSITION COMPRISING A STABILIZING PERFUME COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135319-A1 Multi-phase personal care composition comprising a stabilizing perfume composition CUTA, PARG, POLG RCE1 2938/4885KMT2A 4539/4885HTT 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.